Lichen simplex chronicus (LSC) is a chronic skin condition characterized by thickened, leathery patches of skin that develop as a result of repeated scratching or rubbing. It commonly affects areas such as the neck, scalp, ankles, forearms, and genital regions, often causing intense itching that can significantly impact daily life and sleep.
The condition is driven by a self-perpetuating itch-scratch cycle, where ongoing irritation leads to further skin thickening and increased sensitivity. While topical treatments and anti-itch therapies may provide temporary relief, many patients experience recurring symptoms that are difficult to control long-term.
Clinical trials are essential in advancing more effective treatment options for LSC. At Rejuvenation Dermatology, our clinical studies are designed to evaluate innovative therapies that target the underlying neurological and inflammatory pathways contributing to chronic itching and skin changes.
Participants receive access to investigational treatments in a controlled, medically supervised setting. Each study follows strict ethical and regulatory guidelines, ensuring patient safety while contributing to the development of improved therapeutic options.
Our goal is to reduce itch intensity, break the cycle of chronic scratching, and restore healthier, more resilient skin over time.
STUDY INFO:
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Dupilumab for the Treatment of Pruritus of Lichen Simplex Chronicus (LSC) in Adults.
If you are interested in joining this study, please click here.
EVIDENCE DRIVES BETTER ITCH MANAGEMENT
We believe lichen simplex chronicus treatment should go beyond temporary relief and focus on long-term control. Our clinical trials are designed to evaluate advanced therapies that target the underlying causes of chronic itching and skin thickening, producing meaningful data that improves patient outcomes.
RESEARCH INTEGRATED INTO REAL CLINICAL PRACTICE
All studies are conducted within active dermatology clinics, allowing patients to receive care in a familiar and professional environment. Our dermatologists understand the behavioral and physiological aspects of LSC, ensuring a comprehensive approach to care.
ETHICS ARE NON-NEGOTIABLE
Every lichen simplex chronicus trial undergoes independent ethics board review prior to enrollment. Participants are fully informed, carefully screened, and continuously monitored, with safety protocols that meet and exceed regulatory standards.
STANDARDIZED, NATIONAL EXECUTION
Our multi-site research network operates under centralized oversight and standardized protocols, ensuring consistent execution, high-quality data collection, and reliable outcomes across all participating locations.
Clinical research at Rejuvenation Dermatology is driven by a commitment to advance patient care through evidence-based medicine. Through participating in regulated clinical trials, the organization helps to shape development of safer, more effective dermatologic treatments while ensuring patients receive care that meets the highest ethical and scientific standards.
Participation in clinical research enables Rejuvenation physicians to remain at the forefront of dermatologic innovation and provides patients with access to therapies that may not yet be commercially available.
DERMATOLOGY-LED RESEARCH
Our trials are led by experienced dermatologists who understand the complexities of chronic itch conditions. Physician oversight ensures every participant receives care that is both clinically sound and research-driven.
FOCUS ON THE ITCH-SCRATCH CYCLE
Lichen simplex chronicus requires targeted strategies to break the cycle of irritation and skin damage. Our studies are designed to address both neurological and inflammatory components of the condition.
SAFETY FIRST, ALWAYS
Patient safety is at the core of every study. Strict eligibility criteria, ongoing monitoring, and adherence to Good Clinical Practice guidelines ensure a secure and controlled research environment.
CONSISTENT EXECUTION, TRUSTED RESULTS
Sponsors rely on our ability to recruit efficiently and deliver high-quality, audit-ready data. This structured approach ensures a seamless and reliable experience for participants.
ADVANCING FUTURE TREATMENTS
Participation in clinical trials contributes to the development of new therapies that may improve long-term management of chronic itch conditions like LSC.
Participants may access new therapies while receiving expert dermatological care.
Eligibility depends on the specific study but generally includes individuals with persistent or moderate to severe symptoms.
Lichen Simplex Chronicus is a skin condition caused by repeated scratching or rubbing, leading to thickened, itchy patches of skin.
LICHEN SIMPLEX CHRONICUS CLINICAL TRIALS | REJUVENATION DERMATOLOGY
Rejuvenation Dermatology’s Clinical Trials Department is a national, multi-site research network dedicated to advancing dermatologic care through ethically conducted, regulated clinical research. Integrated within routine clinical practice, the department partners with global pharmaceutical sponsors to evaluate novel therapies and offers early access to innovative treatment options. The team supports industry-sponsored and investigator-initiated trials across a broad range of indications, collaborating closely with sponsors, CROs, investigators, and ethics boards to deliver high-quality data while maintaining a strong commitment to patient safety.
Since its inception, the division has evolved from a single research-focused clinic into a coordinated, multi-province research network. Today, it operates with standardized infrastructure, centralized oversight, and experienced investigators across Canada.
